山东龙辰药业有限公司(以下简称龙辰)是苏州美诺医药科技有限公司的子公司，于2020年12月在中国山东省邹平市经济技术开发区医药产业园成立，总占地面积15万平方米。
公司提供原料药和药品的早期发现、工艺开发、中试和cGMP生产一条龙服务，具备年产600吨原料药的能力。主要产品包括(但不限于)硫辛酸(包括各种形式的硫辛酸)、右旋硫辛酸、钆布醇、噁拉戈利钠等。第二阶段目前正在建设中，预计2023年第一季度投产，生产更多原料药、针剂、胶囊和片剂药品。
As a subsidiary of Suzhou Medinoah Co., Ltd., Shandong Longzen Pharmaceutical Co., Ltd. (referred as Longzen in the following context) was established in December 2020 in the Pharmaceutical Industrial Park of Zouping Economic and Technology Development Zone, Shandong Province, China with a total area of 150k m2.
Longzen provides a one-stop service from early discovery, process development, pilot and cGMP production of APIs and drug products, with capabilities of annual production of 600 metric tons of APIs. The featured products include (but not limited to) Lipoic Acid (including various forms of lipoic acid), R-Lipoic Acid, Gadobutrol and Elagolix, etc. Phase II is currently under construction and expected to be launched by 2023/1Q with production of additional APIs and drug products of injectables, capsules and tablets.
